CN101967159A

CN101967159A - Amino acid Schiff base ligand-containing vanadium oxide compound

Info

Publication number: CN101967159A
Application number: CN2010102847175A
Authority: CN
Inventors: 赵海燕; 邢永恒
Original assignee: Liaoning Normal University
Current assignee: Liaoning Normal University
Priority date: 2009-12-17
Filing date: 2010-09-08
Publication date: 2011-02-09

Abstract

The invention provides an amino acid Schiff base ligand-containing vanadium oxide compound and a preparation method thereof. The toxicity of VO2+ can be reduced by selecting a proper substituent, taking amino acid Schiff base as a ligand, and chemically combining with vanadium to form a tetravalent or pentavalent organic vanadium compound. The vanadium oxide compound has high coordination capability, and can control and stabilize a vanadium oxide coordination compound to fulfill the aim of directionally designing, and regulating molecular configuration and characteristic.

Description

A kind of oxyvanadium compound that contains the amino-acid schiff base part

Technical field

The invention belongs to domain of inorganic chemistry, be specifically related to a kind of preparation and structural characterization thereof of new vanadium oxygen amino-acid schiff base compound.

Technical background

At present, people more and more pay attention to the especially exploitation of heterocyclic medicine and development to the design and the synthetic research of ligand polymer quasi-molecule.Wherein, the research of vanadium oxygen amino-acid schiff base compounds receives much attention.Because though vanadium is few at the plant and animal in-vivo content, its compound has absorbing biology and pharmaceutical activity, especially the para-insulin activity.Vanadium can promote blood sugar transportation and metabolism, and biolipid, DNA and proteinic synthetic also can promote cell fission.Functions such as in addition, vanadate stimulates the blood sugar absorption in addition, sugar is separated and antitumor.In a word, structure, characteristic and the bioactive relation of the cvdmetallorganiccvd ligand compound of research vanadium, to understanding biomacromolecule effect in these metal medicines and the body in depth, the mechanism and the pharmacological action thereof of treatment diabetes disease are significant.But because VO ²⁺Toxic, and be difficult for absorbing, so scientists concentrates on energy on the toxicity of prolong drug action time and reduction medicine.

Summary of the invention

The present invention is part by selecting suitable substituting group with the amino-acid schiff base, forms tetravalence or pentavalent organic vanadium compound with vanadium chemical combination, can reduce toxicity.Because it has very strong coordination ability, and can control and stable vanadium complex, to reach the purpose of directed design, regulatory molecule configuration and characteristic.

A kind of chemical name that contains the oxyvanadium compound of amino-acid schiff base part of the present invention is an alanine salicylic aldehyde 2,2 '-bipyridyl hydration vanadyl compound, and chemical structural formula is

Its preparation method is, with vanadium raw materials vanadylic sulfate (VOSO ₄) or methyl ethyl diketone vanadyl [VO (acac) ₂] and amino acid be dissolved in the mixed solvent of first alcohol and water, stirring at room, and then drip salicylic aldehyde, agitation and filtration, filtrate was left standstill 3～7 days at ambient temperature, had the scarlet crystal to separate out, promptly.

Its synthetic route is seen Fig. 1.

Wherein, described vanadium raw materials is meant (VOSO ₄) or methyl ethyl diketone vanadyl [VO (acac) ₂].Methyl alcohol in the mixed solvent can replace with ethanol and acetonitrile, but best with the effect of the mixed solvent of first alcohol and water.It should be noted that the temperature in the entire synthesis process can not surpass 25 ℃, too highly have side reaction and take place.

Part characterizes instrument to be had: C, H, N analyze with PE 240C type analysis instrument and measure; Infrared spectra is tested (4000-200cm with JASCOFT/IR-480 type spectrograph ^-1); The crystalline structure data are tested with X-ray diffraction analysis (APEX II CCD type diffractometer).

Structural characterization: Infrared spectroscopy is seen Fig. 2, and the main peaks ownership is as follows: ν _O-H3429cm ^-1, ν _C=N1619cm ^-1, ν _V=O957cm ^-1, ν _C-N1156cm ^-1UV spectrum is seen Fig. 3, and the main peaks ownership is as follows: LMCT:256nm, 528nm, 724nm.

[VO (C ₁₀H ₉NO ₃) (C ₁₀H ₈N ₂)] H ₂The molecular structure of O is seen Fig. 4.

Synthetic method of the present invention is simple, and condition is easy to control, has saved raw material, the productive rate height.

The present invention forms tetravalence or pentavalent organic vanadium compound by being part with the amino-acid schiff base with vanadium chemical combination, effectively reduces VO ²⁺Toxicity, can play a significant role aspect diabetes drug treatment and the mechanism research.

Description of drawings

The synthetic route chart of Fig. 1, compound.

Fig. 2, infrared spectrogram.

Fig. 3, ultraviolet spectrogram.

Fig. 4, molecular structure.

Embodiment

Embodiment 1, with 0.5mmol VOSO ₄NH ₂O (0.3mmol, 0.08g, based on 71%VOSO ₄) and 0.5mmol alanine (0.04g, 0.5mmol) be dissolved in the mixed solvent of 11mL methyl alcohol and 1mL water, stirring at room 30min, and then (0.06g 0.5mmol), continues to stir 3h to drip salicylic aldehyde, obtain red tan solution, filter, gained sorrel filtrate is placed at ambient temperature, has the scarlet crystal to separate out after 3 days.The 0.13g that weighs, productive rate: 83% (with VOSO ₄In vanadium be benchmark).Ultimate analysis (C ₂₀H ₁₉N ₃O ₅V)

Measured value: C is 55.51%, and H is 4.47%, and N is 9.69%, and theoretical value: C is 55.56%, and H is 4.43%, and N is 9.72%.

Embodiment 2, with 0.5mmol VOSO ₄NH ₂O (0.3mmol, 0.08g, based on 71%VOSO ₄) and 0.5mmol alanine (0.04g, 0.5mmol) be dissolved in the mixed solvent of 11mL ethanol and 1mL water, drip salicylic aldehyde (0.06g again, 0.5mmol), stirring at room 3h obtains the turbid liquid of sorrel, filters, gained sorrel filtrate is placed at ambient temperature, has the scarlet crystal to separate out after 7 days.The 0.12g that weighs, productive rate: 79% (with VOSO ₄In vanadium be benchmark).Ultimate analysis (C ₂₀H ₁₉N ₃O ₅V) measured value: C is 55.51%, and H is 4.47%, and N is 9.69%, and theoretical value: C is 55.56%, and H is 4.43%, and N is 9.72%.

Claims

1. an oxyvanadium compound that contains the amino-acid schiff base part is characterized in that chemical name is an alanine salicylic aldehyde 2,2 '-bipyridyl hydration vanadyl compound, and chemical structural formula is

2. the described a kind of preparation method who contains the oxyvanadium compound of amino-acid schiff base part of claim 1, it is characterized in that vanadium raw materials and amino acid are dissolved in the mixed solvent of first alcohol and water, stirring at room, and then dropping salicylic aldehyde, agitation and filtration, filtrate was left standstill 3～7 days at ambient temperature, had the scarlet crystal to separate out, promptly;

Wherein, described vanadium raw materials is vanadylic sulfate or methyl ethyl diketone vanadyl.

3. a kind of preparation method who contains the oxyvanadium compound of amino-acid schiff base part according to claim 2 is characterized in that the methyl alcohol in the mixed solvent can replace with ethanol and acetonitrile.

4. the preparation method who contains the oxyvanadium compound of amino-acid schiff base part according to claim 2 is characterized in that the temperature in the building-up process can not surpass 25 ℃, and preferred range is 20～25 ℃.